NDATRANSDERMALSYSTEM2 Generics Approved
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
20
Data completeness
5/8 — Partial
VIVELLE-DOT (estradiol) by Novartis is estrogen receptor agonists [moa]. Approved for menopause, contraception, vaginal atrophy. First approved in 1996.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVELLE-DOT is a transdermal estradiol patch approved in 1996 for hormone replacement therapy in menopause. It delivers estrogen through the skin to manage vasomotor symptoms, vaginal atrophy, and osteoporosis prevention. The drug works as an estrogen receptor agonist, mimicking natural hormone signaling.
$4MPart D
LOE ApproachingStable
Product is in late-stage life cycle with modest Part D spending; commercial teams should prepare for market consolidation and generic competition.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (3)
Worked on VIVELLE-DOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.